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DNA methylation and histone modifications are important epigenetic modifications associated with gene (dys)
regulation. The epigenetic modifications are balanced by epigenetic enzymes, so-called writers and erasers, such as
DNA (de)methylases and histone (de)acetylases. Aberrant epigenetic alterations have been associated with various
diseases, including breast cancer. Since aberrant epigenetic modifications are potentially reversible, they might
represent targets for breast cancer therapy. Indeed, several drugs have been designed to inhibit epigenetic enzymes
(epi-drugs), thereby reversing epigenetic modifications. US Food and Drug Administration approval has been obtained
for some epi-drugs for hematological malignancies. However, these drugs have had very modest anti-tumor
efficacy in phase I and II clinical trials in breast cancer patients as monotherapy. Therefore, current clinical trials
focus on the combination of epi-drugs with other therapies to enhance or restore the sensitivity to such therapies.
This approach has yielded some promising results in early phase II trials. The disadvantage of epi-drugs, however,
is genome-wide effects, which may cause unwanted upregulation of, for example, pro-metastatic genes. Development
of gene-targeted epigenetic modifications (epigenetic editing) in breast cancer can provide a novel approach to
prevent such unwanted events. In this context, identification of crucial epigenetic modifications regulating key
genes in breast cancer is of critical importance. In this review, we first describe aberrant DNA methylation and
histone modifications as two important classes of epigenetic mutations in breast cancer. Then we focus on the
preclinical and clinical epigenetic-based therapies currently being explored for breast cancer. Finally, we describe
epigenetic editing as a promising new approach for possible applications towards more targeted breast cancer
treatment.Introduction
Cells in one organism generally contain the same genetic
information but present very different gene expression
profiles. Epigenetic modifications underlie cell identity
by switching genes on or off during mammalian devel-
opment, without altering the DNA sequence. The herit-
ability of epigenetic modifications plays critical roles in
maintaining cell-type-specific gene expression during
cell divisions [1]. DNA methylation and histone modifi-
cation signatures, especially those on promoter regions
of genes, are well known to be associated with gene
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medium, provided the original work is properDNA methylation, the first identified epigenetic modi-
fication, is written by a family of DNA methyltransfer-
ases (DNMTs). It occurs on carbon 5 of the cytosine
mostly in the context of the dinucleotide cytosine phos-
phate guanine; it is classically known that the DNA
methylation status of promoter regions is inversely cor-
related with gene expression [2]. As such, DNA hyper-
methylation has been suggested to inhibit expression of
retroposons/transposons, and DNA methylation may be
involved in establishing as well as maintaining mono-
allelic patterns of genes (for example, imprinting and
X-chromosome inactivation) [3]. In addition, DNA
methylation is thought to be a key player in prevention
of chromosomal instability, translocations and gene dis-
ruption [1]. DNA methylation was thought to be irre-
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droxymethyl cytosine, providing intermediates in the
process of active DNA demethylation [3,4].
In addition to DNA methylation, various post-translational
histone modifications have been described to be associ-
ated with gene expression [1]. In nucleosomes, the histone
octamer proteins (generally two copies each of H2A, H2B,
H3, and H4) provide the scaffold around which 147 bp of
nuclear DNA is wrapped. Histone tails (especially the
amino-terminal domains of histones) undergo extensive
post-translational histone modifications (for example,
acetylation, methylation, ubiquitination, phosphorylation)
on some residues, especially lysine and arginine [1]
(Figure 1).
Histone modifications as well as DNA methylation are
reversible. A very dynamic form of post-translational his-
tone modification is histone acetylation, which mainly
occurs on lysine residues and involves histone acetyl-
transferases (HATs) and histone deacetylases (HDACs)
(Figure 1). There are four classes of HDACs with 18
members, HDACs 1 to 11 and Sirtuins 1 to 7. Acetyl-
ation of histones reduces their negative charge, thereby,
according to early in vitro studies, reducing the strength
of the histone-DNA interaction and making DNAFigure 1 Epigenetic enzymes and their inhibitors. The figure shows the
and nucleosomes. The nucleosome core consists of a histone octamer (ma
nuclear DNA strand of 147 bp. DNA methylation and hydroxymethylation a
induced by DNA methyltransferases (DNMTs). To inhibit DNA methylation,
Histone tales can be post-transcriptionally modified using enzymes such as
by histone deacetylases (HDACs), and HDAC inhibitors (HDACis) can be useaccessible to transcription factors. Although it is still be-
lieved to be involved in regulation of gene transcription,
acetylation of histone tails would not be sufficient by it-
self to regulate gene transcription in vivo and in the
chromatin context. The effect of histone acetylation on
gene regulation is dependent on various factors, includ-
ing, but not limited to, the position of acetylation [5].
Various epigenetic enzymes are continuously acting to
maintain the balance of epigenetic modifications by in-
ducing (‘writers’) or removing (‘erasers’) epigenetic mod-
ifications. Other epigenetic players bind to epigenetic
modifications (‘readers’) and recruit further re-enforcing
complexes (Figure 1). Malfunctioning of these enzymes
results in aberrant epigenetic modifications (epigenetic
mutations). Since epigenetic enzymes interact with, re-
cruit or suppress each other, while also epigenetic modi-
fications recruit epigenetic enzymes [6], malfunctioning
of any epigenetic enzyme can be sufficient to severely
affect the epigenome and disrupt the normal state of the
cell. The function of epigenetic enzymes is thus vital in
maintaining the normal state of cells.
In cancer, numerous epigenetic enzymes are frequently
mutated and/or dysregulated, resulting in altered epigen-
etic modifications [1,2,7-10]. The dysregulated epigeneticinteractions between epigenetic enzymes (writers, erasers, readers)
inly two copies each of H2A, H2B, H3 and H4) that is wrapped by a
re depicted as black and grey circles, respectively. DNA methylation is
DNMT inhibitors (DNMTis) are used to target and suppress DNMTs.
histone acetyltransferases (HATs). Histone acetylation can be inhibited
d as HDAC suppressors.
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of inhibitors, including DNMT inhibitors (DNMTis),
HDAC inhibitors (HDACis), and the recently developed
inhibitors of histone methyltransferases and HATs. In-
hibitors of epigenetic enzymes used in (pre)-clinical
treatments are so-called epi-drugs.
Epigenetics and breast cancer
Extensive studies on epigenome changes in breast cancer
have been undertaken to understand the role of epigen-
etics in breast cancer and to develop novel epigenetic
therapies. Such studies have demonstrated the associ-
ation of aberrant DNA hypomethylation not only with
cancer in general, but also with breast cancer [11]. In
addition to global blocks of DNA hypomethylation,
which underlies chromosomal instability and disturbed
gene expression patterns, hypermethylation of promoter
regions of, for example, tumor suppressor genes is found
in breast cancer [12]. Decreased levels of DNA hydroxy-
methylation are also observed in breast tumors versus
normal breast tissue [13].
Besides the hypermethylated tumor suppressor genes,
genes involved in DNA repair, apoptosis, metabolism,
cell cycle regulation, cell adherence, metastasis, cellular
homeostasis, and cell growth and genes encoding several
epigenetic enzymes are frequently hypermethylated in
breast cancer [2,12]. Aberrant DNA hypermethylation of
some key genes in breast cancer might be useful as prog-
nostic or diagnostic markers. For instance, aberrant
hypermethylation of genes encoding estrogen receptor
(ER)-α and progesterone receptor (PR) is correlated with
silencing of these genes and with development of ER-
and PR-negative breast cancer. Indeed, some hyper-
methylated genes, such as RASSF1A, are considered as
potential diagnostic markers of breast cancer [2]. Also,
aberrant DNA hypermethylation of the gene PITX2
(paired like homeodomain transcription factor-2) in
breast cancer was recently considered as a marker linked
to tamoxifen resistance [2]. Thus, the DNA methylation
status of such genes might show value as a predictive
marker for therapy response.
Another common occurrence in cancer is the global
reduction of monoacetylated lysine 16 of histone H4
(H4K16) [13]. The loss or low levels of H4K16 acetyl-
ation was suggested as an early event in breast cancer
[7,14] and is associated with altered levels of HDACs
[15]. Moreover, mutated HATs have been reported in
breast cancer [1]. Altered histone methylation patterns
[16] as well as mutated histone methyltransferases are
also observed in breast cancer [1].
Altogether, maintenance of the balance of epigenetic
modifications by epigenetic enzymes is essential for the
regulation of gene expression and the maintenance of
the normal status of cells. Clearly, malfunctioning ofepigenetic enzymes and the subsequent aberrant epigen-
etic modifications are involved in development and pro-
gression of different cancer types, including breast
cancer. Treatments to reverse the aberrant epigenetic
modifications are currently under intensive preclinical
and clinical investigations and are discussed below.
Preclinical studies on epigenetic therapy for
breast cancer
The reversible nature of epigenetic modifications makes
epigenetic mutations attractive targets for epigenetic
therapy of cancer. Currently, intensive research is fo-
cused on inhibiting epigenetic enzymes such as DNMTs
and HDACs. Although aberrant histone methylation
modifications occur in breast cancer, to the best of our
knowledge there is no report describing the effects of
any histone methyltransferase inhibitors on breast can-
cer. DNMTis and HDACis have been tested as thera-
peutic interventions against several tumor types,
including breast cancer. Here, we discuss the different
DNMTis and HDACis and their efficacy in preclinical
breast cancer studies.
DNA methyltransferase inhibitors
DNMTis are used to prevent DNA re-methylation after
cell division and can be classified as nucleoside analogues
and non-nucleoside analogues. Azacitidine (5azaC, Vidaza®,
Celgene Corp., Summit, NJ, USA) and decitabine (5azadC,
Dacogen®, SuperGen, Inc., Dublin, CA, USA) are two
well-known examples of nucleoside analogues [17]. Both
are incorporated into the DNA during replication and, by
forming covalent bonds with DNMTs, they trap them and
block their functions [17].
Azacitidine is considered a global DNMTi and can be
incorporated into both DNA and RNA. For example,
upon treatment of breast cancer cells with azacitidine,
DNA re-methylation was inhibited for 23 out of 26
tested hypermethylated genes in breast cancer. Further
analysis of five selected genes demonstrated their re-
expression [18].
Animal studies further validated the potential thera-
peutic implications of such observations. Assessment of
several therapeutic doses of azacitidine showed associ-
ation of azacitidine with tumor size reduction of xeno-
grafts derived from breast cancer cells [19]. In this study,
treatment of the immunodeficient mice with 0.5 mg/kg
azacitidine for 5 days a week was correlated with growth
inhibition of patient-derived tumors that were engrafted
orthotopically into these mice [19].
Decitabine treatment also prevents DNA re-methylation
and re-activates silenced genes [19]. For example, it was
able to induce tumor necrosis factor related apoptosis-
inducing ligand (TRAIL) in triple-negative breast cancer
cells [20], which can explain how this DNMTi makes
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[21]. Decitabine treatment of animals with orthotopically
implanted breast cancer cells resulted in reduced tumor
volume [22]. Similarly, breast cancer cells pre-treated with
decitabine showed diminished tumor growth upon xeno-
grafting [19].
Importantly, demethylation and re-expression of genes
involved in endocrine therapy response, such as ESR1
(encoding ER-α), can be exploited to overcome endo-
crine therapy resistance in ER-negative breast cancer [2].
Such strategies open new possibilities for otherwise
difficult-to-treat breast cancers.
Non-nucleoside DNMTis include several classes of
natural compounds, such as the polyphenols [17].
Epigallocatechin-3-gallate, a major catechin found in
green tea extract, was found to induce apoptosis in
breast cancer via inhibiting expression of genes such as
VEGF (vascular endothelial growth factor) [23] and it
was shown to induce re-expression of ESR1 in breast
cancer cells [24].
So regardless of the type of agent, inhibition of DNMTs
results in re-expression of tumor suppressor genes associ-
ated with inhibition of growth of cancer cells.
Histone deacetylase inhibitors
HDACis chelate the zinc co-enzyme factor, thereby block-
ing HDACs catalytic activity. HDACis are divided into
four groups: short chain fatty acids (for example, sodium
butyrate, valproic acid), hydroxamic acids (for example,
trichostatin A, vorinostat, panobinostat), cyclic tetrapep-
tides (for example, depsipetide, romidepsin (isostax)), and
benzamides (for example, entinostat, tacedinaline) [20].
HDACis as monotreatment in vitro and in vivo have
several anticancer effects on breast cancer, including
growth arrest, the induction of apoptosis, and cellular
differentiation [20,25-27].
In addition to their efficacy as preclinical monotherapy
in breast cancer cells, HDACis enhance sensitivity to
radiotherapy [20] and cytotoxic agents [28]. For ex-
ample, the combination of vorinostat and TRAIL re-
sulted in significant growth inhibition when compared
with either treatment alone in mice bearing TRAIL-
resistant tumor xenografts [28]. Various HDACis, in-
cluding valproic acid, trichostatin A, and entinostat, have
been shown to play a role in overcoming resistance to
therapies. In this respect, HDACis can be exploited for
overcoming resistance to HER2-targeted therapies [29].
Also, HDACis are well accepted for their anticancer ac-
tivities through promoting re-expression of silenced
genes such as ESR1 in vitro and in vivo [30,31]. More-
over, re-expression of ESR1 re-sensitized breast cancer
cells to the ER-targeted therapy tamoxifen in vitro
[24,32]. Paradoxically, HDACis have non-selective effects
on non-histone proteins, which might cause oppositeeffects. For example, in ER-positive breast cancer cells,
ER-α expression decreased upon treatment with vorino-
stat. This effect can be due to increased acetylation levels
of heat shock proteins, which are known to stabilize the
ER-α protein and inhibit its degradation [33]. Despite these
opposite effects, however, the combination of HDACis and
endocrine therapy acted synergistically in ER-positive
models [34].
FDA approved epi-drugs in oncology
Azacitidine and decitabine are both approved by the
United States Food and Drug Administration (FDA) for
the treatment of myelodysplastic syndrome. Azacitidine
is administered by subcutaneous or intravenous injections
once daily for 7 days followed by 21 days without treat-
ment. Decitabine is given intravenously thrice daily for 3
consecutive days followed by 4 days without treatment. In
the setting of myelodysplastic syndrome, both treatments
provide an objective response (complete + partial re-
sponse) of 16 to 17% compared with no response in
untreated controls. Both regimens show comparable
toxicity profiles, with myelosuppression, gastrointestinal
complaints and constitutional symptoms the most com-
mon side effects [35].
Vorinostat and romidepsin are FDA-approved HDACis
for the treatment of cutaneous T-cell lymphoma; in
addition, romidepsin is approved for the treatment of per-
ipheral T-cell lymphoma [36]. Vorinostat 400 mg orally
once daily induced objective responses in approximately
30% of patients [37]. The most common adverse events in-
clude myelosuppression, gastrointestinal side effects and
fatigue [37]. Administration of romidepsin as a 4-hour in-
fusion on days 1, 8, and 15 of a 28-day cycle with a starting
dose of 14 mg/m2 resulted in an objective response in 34%
of patients with cutaneous T-cell lymphoma [38,39] and in
38% of patients with peripheral T-cell lymphoma [40].
Side-effects are comparable to those of vorinostat.
Efficacy of epi-drugs in breast cancer patients
The efficacy of DNMTis and HDACis in breast cancer
was evaluated in 21 phase I and II studies that enrolled
303 patients with breast cancer (Table 1). In 11 of these
studies (n = 87 patients) epi-drugs were administered to
the patient either as monotherapy or in combination
with another epi-drug. Most of these studies were phase
I studies (64%) in advanced solid tumors and were,
therefore, not primarily aimed to evaluate anti-tumor ef-
ficacy, including only few patients who were, in general,
heavily pre-treated. Nevertheless, epi-drugs in breast
cancer have consistently shown very limited anti-tumor
efficacy on their own. Of 87 patients receiving epi-drugs
as monotherapy, objective responses were observed in
only 9 (10%). The limited efficacy of epi-drugs at the
maximum tolerated dose suggests that they are not well
Table 1 Efficacy of epi-drug monotherapy and combination therapies in breast cancer patients
Epi-drug Phase Co-treatment Number of patients OR/CBR Reference
Monotherapy
Azacitidine I None 11 7/NA [42]
Azacitidine plus valproic acid I 4 0/0 [43]
Decitabine I 4 0/NA [41]
Fazarabine I 3 1/1a [44]
II 14 0/0 [45]
Phenylbutyrate I 5 0/NA [46]
Vorinostat II 14 0/3 [47]
II 3 0/0 [48]
II 26 1/1 [49]
Biomarker study - NA [50]
Vorinostat plus Decitabine I 3 0/0 [51]
Total 87 9 (10%)/NA
Combination therapies
Azacitidine I Erlotinib 1 0/1 [52]
Decitabine I Carboplatin 5 0/NA [53]
Entinostat II Exemestane 64b 4/18 [54]
Valproic acid II 5-Fluoruracil, epirubicin and cyclophosphamide 15 9/NA [55]
I Followed by epirubicine 10 3/7 [56]
Valproic acid plus hydralazine II Standard chemotherapy 3 0/0 [57]
I Doxorubicin plus cyclophosphamide 16 13/NA [58]
Vorinostat I Doxorubicin 5 1/1 [59]
I-II Paclitaxel plus bevacizumab 54 26/42 [60]
II Tamoxifen 43 8/17 [35]
Total 216 64 (30%)/NA
aClinical response. bAn additional 67 patients were randomized to exemestane plus placebo. CBR, objective response + stable disease >6 months); OR, objective
response (partial + complete remission); NA, not available.
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biological efficacy at the epigenetic level was observed;
for instance, pre- and post-treatment tumor biopsies
showed significant reduction in tumor DNA methylation
after decitabine monotherapy [41].
Given that epi-drugs can alter the expression of thera-
peutic targets, this led to the hypothesis that they should
especially be administered as a (re-)sensitizer for drugs
to which intrinsic or acquired resistance exists. This
novel approach has rendered promising results in other
tumor types in clinical trials. Decitabine was shown to
allow the re-expression of the copper transporter CTR1,
which plays a role in cellular platinum-uptake, in pa-
tients with solid tumors and lymphoma [41], and restore
sensitivity to platinum-based chemotherapy in ovarian
cancer [61,62]. A combination of epi-drugs with cyto-
toxic or targeted therapies, such as ER-targeted therapy,
was evaluated in 10 phase I/II studies in 216 breast can-
cer patients. The largest study so far is a phase II study
in which 130 metastatic breast cancer patients wererandomized to exemestane plus placebo (n = 66) or exe-
mestane plus entinostat (n = 64) [54]. These patients had
earlier progressed on a nonsteroidal aromatase inhibitor.
The combination of exemestane plus entinostat signifi-
cantly improved progression-free survival (4.3 versus
2.3 months) and overall survival (28.1 versus 19.8 months)
[54]. In another phase II study in 43 patients with meta-
static breast cancer who progressed on at least one prior
line of endocrine therapy, vorinostat 200 mg twice daily
was combined with tamoxifen [35]. In this study, the ob-
jective response rate was 19% and the clinical benefit rate
(objective response or stable disease >6 months) was 40%.
Baseline high HDAC2 levels correlated with response,
which may prove valuable as a predictive biomarker to se-
lect patients for treatment with HDACis. Finally, in a
phase I/II study in 54 patients with metastatic breast can-
cer, vorinostat 200 to 300 mg twice daily on days 1 to 3, 8
to 10, and 15 to 17 was added to paclitaxel plus bevacizu-
mab [60]. This combination resulted in a 49% objective re-
sponse rate (partial + complete remission) and 78% clinical
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Serial biopsies, available from seven patients, showed
an increase in acetylation of heat shock protein 90 and
α-tubulin.
Although there is preclinical evidence for enhanced ef-
ficacy of HER2-targeted therapies when combined with
epi-drugs, results from clinical studies are awaited.
In conclusion, epi-drugs have limited anti-tumor effi-
cacy in breast cancer patients at the maximum tolerated
dose when administered as monotherapy, but can be ad-
ministered safely. However, expected epigenetic changes,
such as decreased tumor DNA methylation [41], in-
creased histone acetylation [60], and upregulation of
gene expression [58], are observed after their administra-
tion in clinical breast cancer studies. Current studies
suggest a potential role for epi-drugs in combination
with chemotherapeutics and targeted therapies to en-
hance or restore the sensitivity to these drugs.
Current breast cancer trials evaluating epi-drugs
Ongoing trials increasingly apply epi-drugs to specific
subgroups rather than to the general breast cancer
population. Much work is performed on (re-)sensitization
of endocrine-resistant tumors to endocrine therapy. In
patients with triple-negative or hormone-refractory meta-
static breast cancer, azacitidine is combined with entino-
stat; although the response rate is the primary endpoint in
this study, the effects on ER and PR expression will be eval-
uated as secondary endpoints (NCT01349959). A novel,
non-invasive way to measure ER expression is by molecu-
lar imaging using positron emission tomography (PET)
and 18 F-fluoroestradiol (FES) as a tracer [63]. This tool fa-
cilitates the assessment of ER expression during treatment.
In a study, hormone-refractory patients are being treated
with daily vorinostat for 2 weeks, followed by a treatment
with an aromatase inhibitor for 6 weeks (NCT01153672).
Cycles are repeated every 8 weeks until progression. As a
secondary endpoint, changes in ER expression will be mea-
sured using serial FES-PET imaging. Panobinostat and dec-
itabine are also being evaluated to sensitize triple-negative
breast cancer patients to endocrine therapy in phase I/II
studies (NCT01194908, NCT01105312).
The use of DNMTis and HDACis as chemo-sensitizers
is also being evaluated in various breast cancer trials (for
example, NCT00748553, NCT00368875). Among the eval-
uated combinations are azacitidine with Nab-paclitaxel
(Abraxane®, Abraxis Bioscience, Los Angeles, CA, USA),
valproic acid with FEC, and vorinostat with paclitaxel plus
bevacizumab. Finally, sensitization to HER2-targeted ther-
apy will be evaluated in a limited number of studies. One
phase I/II study evaluated 200 mg vorinostat twice daily on
days 1 to 14 combined with trastuzumab 6 mg/kg once
every 3 weeks. This study enrolled 16 patients and was ter-
minated due to low response rate (NCT00258349).Another study will evaluate the safety and efficacy of vori-
nostat combined with the tyrosine kinase inhibitor lapatinib
(NCT01118975). Also, several studies using panobinostat to
sensitize breast cancer to trastuzumab (NCT00788931,
NCT00567879), and lapatinib (NCT00632489) have re-
cently been completed and results are awaited. All trials
were phase I or II. An overview of ongoing trials with
DNMTis and/or HDACis in breast cancer is provided in
Table 2.
Epigenetic editing
Despite the above-described promises, epi-drugs affect
genes in a genome-wide manner, as well as inhibit writers
and erasers, which generally also modify non-chromatin
proteins. Such aspecific mechanisms of action result in un-
wanted effects, including upregulation of prometastatic
genes [64] or of genes encoding drug resistance-associated
proteins [65]. To fully exploit the reversible nature of
epigenetic mutations while avoiding unwanted effects,
epigenetic therapy can be improved using gene targeting
approaches: by fusing a writer or eraser of a particular
epigenetic mark to a self-engineered DNA binding domain,
rewriting of the epigenetic signature of a selected target
gene (epigenetic editing) is achieved [6]. To obtain
sequence-targeted DNA binding, zinc finger proteins
(ZFPs), triplex forming oligos, transcription activator-like
effectors (TALEs), or catalytically inactive Cas proteins of
the clustered regularly interspaced short palindromic re-
peats system [66,67] can be fused to the catalytic domains
of epigenetic enzymes (epigenetic effector domains) [6,68]
or to epi-drugs [69]. The epigenetic effector domain of an
epigenetic editing tool will subsequently overwrite epigen-
etic modifications at the targeted gene. Because of cellular
epigenetic maintenance processes, edited epigenetic modi-
fications (or sets thereof) might remain on the DNA or
histone tails, even after removal of the epigenetic editing
tool. Moreover, written epigenetic modifications can spread
along the target gene [70,71] due to subsequent recruit-
ment of endogenous epigenetic enzymes [72,73]. Interest-
ingly, adequately rewritten epigenetic modifications might
be inherited by subsequent cell generations [74], thereby
allowing permanent changes to genome functioning with-
out changing genomic sequences. Altogether, epigenetic
editing provides a promising novel avenue to interfere with
gene expression levels in a persistent manner.
As epigenetic editing targets a gene directly at the
DNA level, this targeting of generally two copies of
DNA offers advantages over targeting multiple copies of
or different isoforms of proteins or RNA. Moreover,
since RNA and protein molecules are constantly being
expressed, their sustained inhibition requires continuous
administration of inhibitors or potentially harmful inte-
gration of the (RNA interference) transgene expression
cassette into the host genome. Epigenetic editing allows
Table 2 Overview of current clinical trials evaluating DNMT-inhibitors and HDAC-inhibitors in breast cancer




Azacitidine Advanced BC Entinostata Objective response rate 60 II R 01349959





The maximum tolerated dose of
decitabine and panobinostat
60 I/II R 01194908
FdCyd Solid tumors, including BC Tetrahydrouridine To determine the safety of FdCyd 20 I R 01479348
FdCyd Solid tumors, including BC Tetrahydrouridine To determine PFS and/or response rate
of FdCyd plus tetrahydrouridine
185 I R 00978250
EGCG Newly diagnosed BC - To determine whether EGCG can affect
proliferation rate and induce apoptosis
20 II R 00949923
Newly diagnosed BC - To evaluate the effects of EGCG on various
biomarkers
32 II A 00676793
Stage I-III BC - To determine the safety and maximum
tolerated dose of EGCG
40 I A 00516243
HDAC
inhibitor
Vorinostat BC Lapatinib Clinical benefit rate 47 I/II R 01118975
Recurrent/metastatic BC - To evaluate the safety of vorinostat 49 I/II A 00416130
Advanced BC Capecitabine The maximum tolerated dose, safety,
and efficacy of vorinostat plus capecitabine





The maximum tolerated dose, and objective
response rate of vorinostat in combination
with paclitaxel/bevacizumab
58 I/II U 00368875
Metastatic BC Ixabepilone Dose limiting toxicity 56 I A 01084057
Hormone-refractory BC Aromatase inhibitor Clinical benefit rate 14 II R 01720602
Locally advanced BC Paclitaxel/trastuzumab To determine the recommended
phase II dose
54 I/II U 00574587
Hormone-refractory BC Aromatase inhibitor Clinical benefit rate 20 II R 01153672
Newly diagnosed BC Nab-paclitaxel/
carboplatin
Pathologic complete response rate 74 II A 00616967
HIV + with solid tumor,
including BC





Maximum tolerated dose 24 I A 00838929
Entinostat Locally recurrent/metastatic
ER + BC, or NSCLC
±Exemestane Pharmacokinetics of entinostat in
fasted and fed subjects
28 I R 01594398
Newly diagnosed TNBC Anastrozole Safety, tolerability and recommended
phase II dose (phase I cohort); change in
proliferation, ER/PR expression (phase II cohort)
41 I/II R 01234532
HER2-positive
metastatic BC
Lapatinib Recommended phase II dose (phase I cohort);
objective response rate (phase II cohort)
70 I/II R 01434303
Advanced BC Azacitidinea Objective response rate 60 II R 01349959
Panobinostat Metastatic TNBC Letrozole Maximum tolerated dose, adverse events
(phase I cohort); response rate (phase II cohort)
48 I/II R 01105312
Advanced/metastatic TNBC Decitabineb
(±tamoxifen)
The maximum tolerated dose of decitabine
and panobinostat
60 I/II R 01194908
HER2-negative locally
recurrent/metastatic BC
- Objective response rate 118 II A 00777049
VPA Newly diagnosed locally
advanced/metastatic BC
FEC Pathologic response rate 55 II R 01010854
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Table 2 Overview of current clinical trials evaluating DNMT-inhibitors and HDAC-inhibitors in breast cancer (Continued)
Newly diagnosed BC - To determine whether VPA levels correlate
with leukocyte and tumor histone acetylation
33 NA R 01007695
Depsipeptide Solid or hematologic
malignancy, including BC
- Safety, tolerability, maximum tolerated dose
and pharmacokinetics
132 I R 01638533
N = estimated enrolment. Status: A = active, not recruiting; C = completed; R = recruiting; U = unknown. a,bCross-referenced within table. BC, breast cancer; DNMT,
DNA methyltransferase; EGCG, epigallocatechin-3-gallate; ER, estrogen receptor; HDAC, histone deacetylase; NA, not applicable; NSCLC, non small-cell lung cancer;
PFS, progression-free survival; PR, progesterone receptor; TNBC, triple-negative breast cancer; VPA, valproic acid.
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of the RNA production. Alternatively, for upregulation
of a gene’s expression level, epigenetic editing tools
can be engineered to remove epigenetic repressive
marks and/or induce activating marks at selected loci.
Such overwriting of repressive signatures will allow
transcription of alternative isoforms to take place, in
their natural ratios. For example, for upregulation of
tumor suppressor genes that are frequently silenced by
epigenetic mutations, activating the expression from
their endogenous DNA loci better mimics nature than
administration of ectopic cDNA expression constructs,
which result in overexpression of only one isoform of a
gene.
Proofs of concept for locus-specific epigenetic over-
writing have been described for numerous epigenetic
effector domains [6]. To date, 10 papers describe epi-
genetic editing on endogenous genes. Using engineered
ZFPs, we showed that targeted DNA methylation is
instructive in gene expression downregulation (for
example, of MASPIN [75], VEGF-A [76], and EpCAM
[77]). Interestingly, targeted DNA demethylation could
be induced, which was effective in upregulating the ex-
pression of the targeted gene ICAM-1 [78]. We also
demonstrated that writing the repressive histone
methylation modification H3K9me2 on the Her2/neu
gene induced Her2/neu protein downregulation, which
in turn inhibited cancer cell growth [79]. Our findings
for an overexpressed oncogene validated results of an
earlier report on downregulation of VEGF-A [70].
Moreover, targeted DNA methylation of the SOX2 pro-
moter prevented growth of breast cancer cells, also
upon removal of the epigenetic writer [75]. Others re-
cently joined the field and demonstrated the power of
epigenetic editing as a unique research tool in address-
ing epigenetic control of gene expression regulation
[80,81]. Interestingly, active DNA demethylation has
also been demonstrated using engineered TALE-TET2
fusions [82] or by fusing a DNA repair enzyme to engi-
neered ZFPs [83]. As targeting of genes has recently
become widely feasible [84], epigenetic editing opens
new avenues towards 'the druggable genome', and since
multiplex gene targeting is currently feasible, cancer
therapy approaches might also benefit from such
progress.Conclusion
Epigenetic mutations, including aberrant DNA methyla-
tion and histone modifications, are associated with
breast cancer development and therapy resistance. Aber-
rant DNA methylation and histone acetylation can be re-
versed by DNMTis and HDACis. Several DNMTis and
HDACis are FDA approved, albeit not so far for the
treatment of patients with breast cancer. These drugs
can induce apoptosis, alter gene expression, and reverse
therapy resistance in preclinical models. In clinical stud-
ies, DNMTis and HDACis have shown very modest anti-
tumor activity as monotherapy, although effects on gene
expression can be observed. Current clinical trials, there-
fore, mainly focus on the combination of these drugs
with chemotherapeutics and targeted therapies. Despite
their promise, a disadvantage of DNMTis and HDACis
is their genome-wide function and non-chromatin ef-
fects. Epigenetic editing of a single gene results in gene
expression modulation, and thereby fully exploits the re-
versibility of epigenetic modifications as therapeutic tar-
gets while reducing off-target effects. Epigenetic editing
and other targeted approaches thus provide alternatives
to current epigenetic therapies for breast cancer.
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